Explore BioBoost LabsBPC-157
Body Protection Compound — what it is, what the name means, its structure, where it came from, and why it was created. Factual, sourced, no hype.
What the name means
BPC stands for Body Protection Compound. The 157 is a sequence designation — a lab identifier for this specific short fragment.
So the name is almost literal: it is a small piece of a larger “body-protection” protein, catalogued as fragment 157. Nothing mystical — it points straight back to where the molecule was found and what it was studied for.
What it actually is
BPC-157 is a synthetic peptide — a short chain of 15 amino acids (a “pentadecapeptide”), joined by 14 peptide bonds.
It is a partial sequence: a copy of one active stretch of a much larger protective protein originally identified in gastric (stomach) juice. It is not the whole natural protein — it is the specific fragment researchers found was doing the interesting work, distilled down so it can be made and studied precisely.
Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Because that sequence comes from a region built to survive stomach acid, the fragment is unusually stable — one practical reason it drew so much research attention.
Where it came from
BPC-157 traces back to research on the proteins that let the stomach lining protect and repair itself in a harsh, acidic environment.
In the 1990s a research group led by Predrag Sikirić at the University of Zagreb (Croatia) studied a body-protection compound present in gastric juice and isolated the short, stable fragment now known as BPC-157. Nearly all of the foundational work on this peptide comes from that lineage of laboratories.
Why it was created — the thought process
The idea was elegant: the stomach constantly protects and rebuilds itself under acid attack, so the peptides responsible for that protection might carry general tissue-protection and repair signals.
Rather than work with the entire, unwieldy protein, the researchers asked a sharper question: what is the smallest active piece? Isolating that minimal fragment made it something you could actually synthesize, standardize, and study — and that minimal fragment is BPC-157. That is the whole thought process: find the body’s own protective signal, then distill it to its active core.
How it is made
Because it is only 15 amino acids long, BPC-157 is built by solid-phase peptide synthesis (SPPS).
The chain is assembled one amino acid at a time on a tiny solid resin bead — couple, wash, deprotect, repeat — following the exact 15-residue sequence. It is then cleaved off the resin and purified by reverse-phase HPLC, and its identity is confirmed by mass spectrometry. Nothing is extracted from an animal; it is chemically synthesized to an exact, verifiable sequence and mass. See how a peptide is made and how it is tested.
What the research actually shows — honestly
Most BPC-157 research is preclinical — cell and animal models, largely from the original Croatian group and collaborators.
It has been studied for tissue-protection and repair signalling. But human clinical efficacy is not established, long-term human safety data is limited, and it is a research compound, not an approved medicine. We present the science and its origins so you can understand what BPC-157 is — not to suggest a use. Any decision about human use belongs with a licensed physician, and these materials are for laboratory research only.
Selected research & sources
The items below are drawn from the peer-reviewed literature (PubMed) and describe results observed in research models. They are listed so the evidence can be examined at its source — not to suggest any use.
- Musculoskeletal soft tissue (tendon, ligament, skeletal muscle): healing effects reported across injury types, in predominantly small-rodent models, not confirmed in humans. Gwyer, Wragg & Wilson, Cell Tissue Res. 2019. doi.org/10.1007/s00441-019-03016-8
- Wound-healing models (incisional, excisional, burn, diabetic-ulcer, alkali): effects described with associated vascular and clotting-resolution changes. Seiwerth et al., Front Pharmacol. 2021. doi.org/10.3389/fphar.2021.627533
- Tendon fibroblast mechanism: increased explant outgrowth, migration and survival under oxidative stress, linked to FAK–paxillin signalling (in vitro). Chang et al., J Appl Physiol. 2011. doi.org/10.1152/japplphysiol.00945.2010
- Gastrointestinal integrity and fistula models in rats: reported healing of diverse fistulas and anastomoses. Sikiric et al., Curr Pharm Des. 2020. doi.org/10.2174/1381612826666200424180139
- Cytoprotection framework and interaction with the nitric-oxide system. Sikiric et al., Gut Liver. 2020. doi.org/10.5009/gnl18490
- Central-nervous-system models discussed within a gut–brain-axis framework. Vukojevic et al., Neural Regen Res. 2022. doi.org/10.4103/1673-5374.320969
- Brain–gut axis, further review of rodent findings. Sikiric et al., Pharmaceuticals. 2023. doi.org/10.3390/ph16050676
- Intestinal anastomosis healing in rats. Bajramagic et al., Pharmaceuticals. 2024. doi.org/10.3390/ph17081081
A large share of this literature originates from a single research group (Sikiric and colleagues) — a concentration worth noting when weighing the evidence. Human clinical efficacy is not established, long-term human safety data is limited, and BPC-157 is not an approved medicine in the U.S. or EU — it is handled as a research compound (RUO).
◆ A reference, not a recommendation
This page explains what BPC-157 is and where it came from — the science and the story — not who should use anything, or how. These are research materials for laboratory research only; nothing here is medical, dosing, or treatment advice.
Research-use-only educational content. Factual overview; human efficacy not established.